Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011753 | 0.88 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL1010265 | 0.86 | FKBP1A (0.46) | FKBP1AF2HPGDTDP1ELANE | |
| SCHEMBL1011983 | 0.84 | SLC6A4 (0.54) | FKBP1AALDH1A1HPGDSMN1; SMN2SLC6A3 | |
| SCHEMBL1010262 | 0.83 | L3MBTL1 (0.43) | ALDH1A1HPGDTDP1TSHRSLC6A3 | |
| SCHEMBL7652967 | 0.82 | CYP2C19 (0.46) | ALDH1A1TSHRSLC6A3 | |
| SCHEMBL1010278 | 0.81 | SLC6A4 (0.43) | ALDH1A1TSHRSLC6A3 | |
| SCHEMBL9356307 | 0.77 | ALDH1A1 (0.54) | FKBP1AALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL9352186 | 0.77 | ALDH1A1 (0.54) | FKBP1AALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL1012557 | 0.76 | HTR2C (0.51) | HPGDNPC1RAB9ASMN1; SMN2ELANE | |
| SCHEMBL21869792 | 0.75 | FKBP1A (0.50) | FKBP1AALDH1A1TDP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| US-6486323-B1 | Process for producing optically active tropinonemonocarboxylic acid derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | FKBP1A 2654/4885ALDH1A1 57/4885F2 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.